Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study

Radiother Oncol. 2023 Mar:180:109462. doi: 10.1016/j.radonc.2022.109462. Epub 2023 Jan 9.

Abstract

Background and purpose: We evaluated the postoperative radiotherapy (PORT) effects on hepatocellular carcinoma (HCC) prognosis and recurrence in patients who underwent narrow-margin (<1.0 cm) hepatectomy (NH).

Materials and methods: This two-arm cohort study based on the phase II study compared NH with or without PORT in patients with HCC. All patients underwent NH; 76 patients who received PORT following NH in the phase II study were assigned to the NH + RT group, and 171 who underwent NH alone were assigned to the NH group. Propensity score matching (PSM) was used to balance clinicopathological characteristic differences between groups.

Results: Before PSM, the 5-year overall survival (OS) rates between groups differed significantly (72.2 % vs 60.7 %, P = 0.017). Moreover, the 5-year disease-free survival (DFS) rate was significantly higher in the NH + RT group (51.4 % vs 35.7 %, P = 0.002). After PSM, the between-group difference in OS rates remained high (P = 0.045); the 5-year OS rates were 74.7 % and 63.6 % in the NH + RT and NH groups, respectively. Similarly, the DFS rate remained significantly higher in the NH + RT group (P = 0.001); the 5-year DFS rates were 56.3 % and 31.6 %, respectively. Furthermore, both before and after PSM, patients in the NH + RT group showed significantly lower early, intrahepatic, and extrahepatic recurrence rates than those in the NH group.

Conclusions: PORT may have significant OS and DFS benefits in patients with HCC undergoing NH.

Keywords: Hepatocellular Carcinoma; Narrow-Margin Hepatectomy; Postoperative Radiotherapy; Prognosis; Recurrence.

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Carcinoma, Hepatocellular* / radiotherapy
  • Carcinoma, Hepatocellular* / surgery
  • Cohort Studies
  • Hepatectomy
  • Humans
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / radiotherapy
  • Liver Neoplasms* / surgery
  • Neoplasm Recurrence, Local / pathology
  • Prognosis
  • Propensity Score
  • Retrospective Studies